The EU is likely to have its first two anti-COVID-19 monoclonal antibody products available shortly, after the European Medicines Agency gave the green light to Regeneron Pharmaceuticals, Inc./Roche’s Ronapreve and Celltrion, Inc.’s Regkirona.
On 11 November the EMA announced that its human drugs committee, the CHMP, had recommended authorizing Ronapreve (casirivimab/imdevimab) for treating...








